TMDX
TransMedics Group, Inc.
$77.87
-1.13
(-1.43%)
Mkt Cap
2.69B
Volume
733,651
52W Range
60.105-156
Sector
Healthcare
Beta
1.93
EPS (TTM)
4.42 USD
P/E Ratio
17.62
Revenue (TTM)
668.47M USD
Rev Growth (5Y)
+88.2%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$148.38
Undervalued
strong signal
47.5% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 605.49M | 441.54M | 241.62M | 93.46M | 30.26M | 25.64M | 23.60M | 13.02M | 7.68M | 6.21M |
| Net Income | 190.29M | 35.46M | (25.03M) | (36.23M) | (44.22M) | (28.75M) | (33.55M) | (23.76M) | (20.82M) | (24.07M) |
| EPS | 5.60 | 1.07 | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| Free Cash Flow | 133.59M | (80.94M) | (192.09M) | (57.72M) | (32.38M) | (30.72M) | (32.45M) | (26.40M) | (23.36M) | (25.59M) |
| FCF / Share | 3.93 | -2.44 | -5.91 | -1.95 | -1.17 | -1.24 | -2.28 | -1.37 | -1.61 | -1.77 |
| Operating CF | 192.84M | 48.80M | (13.03M) | (45.82M) | (28.86M) | (30.27M) | (32.29M) | (25.98M) | (23.10M) | (24.11M) |
| Total Assets | 1.07B | 804.08M | 706.05M | 277.15M | 134.89M | 152.03M | 105.30M | 42.16M | 37.00M | 58.10M |
| Total Debt | 469.69M | 518.29M | 515.95M | 67.56M | 43.80M | 34.66M | 34.15M | 33.67M | 8.65M | 8.41M |
| Cash & Equiv | 488.37M | 336.65M | 394.81M | 201.18M | 25.58M | 24.58M | 20.09M | 20.24M | 11.94M | 9.84M |
| Book Value | 473.10M | 228.60M | 137.20M | 187.38M | 67.85M | 103.89M | 54.65M | (4.83M) | (168.72M) | 38.79M |
| Return on Equity | 0.40 | 0.16 | -0.18 | -0.19 | -0.65 | -0.28 | -0.61 | N/A | N/A | -0.62 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 189.95M | 173.93M | 160.76M | 143.82M | 157.37M | 143.54M | 121.62M | 108.76M | 114.31M | 96.85M | 81.17M | 66.43M |
| Net Income | 14.68M | 7.32M | 105.38M | 24.32M | 34.91M | 25.68M | 6.86M | 4.22M | 12.19M | 12.20M | 4.03M | (25.42M) |
| EPS | 0.42 | 0.21 | 3.08 | 0.71 | 1.03 | 0.76 | 0.20 | 0.13 | 0.37 | 0.37 | 0.12 | -0.78 |
| Free Cash Flow | 10.22M | (12.12M) | 19.00M | 61.95M | 82.53M | (29.89M) | 6.06M | (41.35M) | 1.96M | (47.61M) | (33.51M) | (114.59M) |
| FCF / Share | 0.30 | -0.35 | 0.56 | 1.82 | 2.43 | -0.89 | 0.18 | -1.24 | 0.06 | -1.45 | -1.03 | -3.51 |
| Operating CF | 17.31M | 24.53M | 34.51M | 69.57M | 91.61M | (2.85M) | 19.66M | 6.86M | 25.72M | (3.44M) | 8.30M | (6.87M) |
| Total Assets | 1.46B | 1.43B | 1.07B | 946.03M | 890.52M | 837.53M | 804.08M | 785.57M | 758.58M | 723.83M | 706.05M | 689.23M |
| Total Debt | 867.72M | 863.41M | 469.69M | 519.35M | 518.82M | 518.41M | 518.29M | 518.15M | 516.49M | 516.22M | 515.95M | 515.65M |
| Cash & Equiv | 472.68M | 461.74M | 488.37M | 466.17M | 400.57M | 310.14M | 336.65M | 330.09M | 362.75M | 350.22M | 394.81M | 427.11M |
| Book Value | 518.05M | 494.01M | 473.10M | 355.20M | 318.10M | 266.31M | 228.60M | 209.92M | 189.89M | 159.47M | 137.20M | 126.46M |
| Return on Equity | 0.03 | 0.01 | 0.22 | 0.07 | 0.11 | 0.10 | 0.03 | 0.02 | 0.06 | 0.08 | 0.03 | -0.20 |
TMDX News
TransMedics Group Inc (TMDX) Shares Fall 5.8% -- What GF Score of 74 Tells Investors
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
TransMedics Group (NASDAQ:TMDX) Shares Up 4.5% After Insider Buying Activity
2 Stocks Down 28% and 34% to Buy and Hold
TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?